Met Life Investment Management, LLC Deciphera Pharmaceuticals, Inc. Transaction History

Met Life Investment Management, LLC

$20.1 Billion
Q3 2025

37 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$13.58 - $17.36 $369,647 - $472,539	27,220 New	27,220 $428,000
Q2 2023 Apr 29, 2024	BUY	$13.28 - $15.96 $361,481 - $434,431	27,220 New	27,220 $383,000
Q1 2023 May 09, 2024	BUY	$14.26 - $22.1 $388,157 - $601,562	27,220 New	27,220 $421 Million
Q1 2023 May 15, 2023	BUY	$14.26 - $22.1 $53,503 - $82,919	3,752 Added 15.99%	27,220 $420,000
Q4 2022 Jun 14, 2023	SELL	$14.85 - $19.04 $55,717 - $71,438	-3,752 Reduced 13.78%	23,468 $384,000

Q3 2022 Jun 14, 2023	SELL	$12.38 - $20.23 $46,449 - $75,902	-3,752 Reduced 13.78%	23,468 $434,000
Q2 2022 Jun 20, 2023	SELL	$9.11 - $13.98 $34,180 - $52,452	-3,752 Reduced 13.78%	23,468 $308,000
Q1 2022 May 10, 2024	BUY	$6.87 - $11.11 $161,225 - $260,729	23,468 New	23,468 $217,000
Q1 2022 Jun 20, 2023	SELL	$6.87 - $11.11 $25,776 - $41,684	-3,752 Reduced 13.78%	23,468 $217,000
Q1 2022 Mar 22, 2023	BUY	$6.87 - $11.11 $57,213 - $92,524	8,328 Added 55.01%	23,468 $217,000
Q1 2022 May 12, 2022	BUY	$6.87 - $11.11 $57,213 - $92,524	8,328 Added 55.01%	23,468 $218,000
Q4 2021 Jun 21, 2023	SELL	$7.7 - $37.13 $93,016 - $448,530	-12,080 Reduced 44.38%	15,140 $147,000
Q3 2021 Jun 21, 2023	SELL	$26.46 - $37.15 $319,636 - $448,772	-12,080 Reduced 44.38%	15,140 $514,000
Q2 2021 Jun 21, 2023	SELL	$32.73 - $47.95 $395,378 - $579,236	-12,080 Reduced 44.38%	15,140 $554,000
Q1 2021 May 17, 2024	SELL	$40.39 - $56.73 $487,911 - $685,298	-12,080 Reduced 44.38%	15,140 $678,000
Q1 2021 Jun 26, 2023	SELL	$40.39 - $56.73 $487,911 - $685,298	-12,080 Reduced 44.38%	15,140 $679 Million
Q4 2020 May 24, 2024	SELL	$51.77 - $66.18 $75,480 - $96,490	-1,458 Reduced 8.78%	15,140 $864,000
Q4 2020 Jun 22, 2023	SELL	$51.77 - $66.18 $625,381 - $799,454	-12,080 Reduced 44.38%	15,140 $864,000
Q4 2020 Mar 22, 2023	SELL	$51.77 - $66.18 $75,480 - $96,490	-1,458 Reduced 8.78%	15,140 $864,000
Q4 2020 Feb 16, 2021	SELL	$51.77 - $66.18 $75,480 - $96,490	-1,458 Reduced 8.78%	15,140 $864,000
Q3 2020 Jun 26, 2023	SELL	$43.8 - $58.16 $465,243 - $617,775	-10,622 Reduced 39.02%	16,598 $851,000
Q2 2020 May 24, 2024	SELL	$37.05 - $65.03 $393,545 - $690,748	-10,622 Reduced 39.02%	16,598 $991 Million
Q2 2020 Jun 26, 2023	SELL	$37.05 - $65.03 $393,545 - $690,748	-10,622 Reduced 39.02%	16,598 $991,000
Q2 2020 Mar 22, 2023	BUY	$37.05 - $65.03 $291,805 - $512,176	7,876 Added 90.3%	16,598 $991,000
Q2 2020 Aug 14, 2020	BUY	$37.05 - $65.03 $291,805 - $512,176	7,876 Added 90.3%	16,598 $991,000
Q1 2020 Jul 12, 2023	SELL	$33.63 - $69.4 $622,087 - $1.28 Million	-18,498 Reduced 67.96%	8,722 $359,000
Q4 2019 Jul 12, 2023	SELL	$31.7 - $69.93 $586,386 - $1.29 Million	-18,498 Reduced 67.96%	8,722 $542,000
Q4 2019 Mar 22, 2023	BUY	$31.7 - $69.93 $36,740 - $81,048	1,159 Added 15.32%	8,722 $542,000
Q4 2019 Feb 14, 2020	BUY	$31.7 - $69.93 $36,740 - $81,048	1,159 Added 15.32%	8,722 $543,000
Q3 2019 Jul 12, 2023	SELL	$19.95 - $38.85 $392,157 - $763,674	-19,657 Reduced 72.22%	7,563 $256,000
Q3 2019 Mar 22, 2023	BUY	$19.95 - $38.85 $29,665 - $57,769	1,487 Added 24.47%	7,563 $256,000
Q3 2019 Nov 14, 2019	BUY	$19.95 - $38.85 $150,881 - $293,822	7,563 New	7,563 $257,000
Q2 2019 Jul 12, 2023	SELL	$21.05 - $26.21 $413,779 - $515,209	-19,657 Reduced 72.22%	7,563 $171 Million
Q4 2018 Feb 14, 2019	SELL	$19.08 - $36.14 $115,930 - $219,586	-6,076 Closed	0 $0
Q3 2018 Jul 13, 2023	SELL	$33.57 - $42.1 $782,315 - $981,098	-23,304 Reduced 85.61%	3,916 $151,000
Q3 2018 Mar 22, 2023	SELL	$33.57 - $42.1 $583,849 - $732,203	-17,392 Reduced 74.11%	6,076 $235,000
Q3 2018 Nov 14, 2018	BUY	$33.57 - $42.1 $203,971 - $255,799	6,076 New	6,076 $235,000

Others Institutions Holding DCPH

# of Institutions

Shares Held

212K

Call Options Held

500

Put Options Held

View Full List

About Deciphera Pharmaceuticals, Inc.

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

More about DCPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account